- Home
- PHAT
as 06-27-2025 12:33pm EST
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | FLORHAM PARK |
| Market Cap: | 727.5M | IPO Year: | 2019 |
| Target Price: | $16.40 | AVG Volume (30 days): | 4.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.21 - $19.71 | Next Earning Date: | 08-07-2025 |
| Revenue: | $81,859,000 | Revenue Growth: | 3055.70% |
| Revenue Growth (this year): | 195.45% | Revenue Growth (next year): | 106.76% |
Stock Insider Trading Activity of Phathom Pharmaceuticals Inc. (PHAT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Topper James N | PHAT | Director | May 21 '25 | Buy | $3.86 | 3,780 | $14,609.32 | 59,403 | |
| Topper James N | PHAT | Director | May 13 '25 | Buy | $3.24 | 7,420 | $24,462.49 | 59,403 | |
| Topper James N | PHAT | Director | May 9 '25 | Buy | $3.28 | 48,203 | $152,916.63 | 59,403 | |
| Parikh Asit | PHAT | Director | May 6 '25 | Buy | $2.50 | 10,000 | $24,984.50 | 95,500 | |
| Henderson Molly | PHAT | CFO and CBO | Apr 7 '25 | Sell | $4.55 | 3,678 | $16,739.68 | 89,868 |
Latest Phathom Pharmaceuticals Inc. News
PHAT Breaking Stock News: Dive into PHAT Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
5 days ago
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
MT Newswires
12 days ago
Phathom Pharmaceuticals' Heartburn Drug Receives Regulatory Exclusivity in FDA Orange Book Update
GlobeNewswire
12 days ago
Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032
Zacks
19 days ago
Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade
MT Newswires
21 days ago
Sector Update: Health Care Stocks Rise Late Afternoon
MT Newswires
21 days ago
Top Midday Gainers
MT Newswires
21 days ago
Sector Update: Health Care Stocks Advance in Afternoon Trading
Compare PHAT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PHAT Phathom Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.